• 36 out of 37 COVID-19 patients treated in the trial, representing approximately 97.3% of the patients, reported they had all symptoms eliminated within the 6-day treatment period save for loss or reduced sense of taste and smell (“Sensory Dysfunction”) and occasional cough. The highest number of different symptoms reported for any one individual was 14.
• 15 out of the 36 patients experienced Sensory Dysfunction prior to receiving treatment. Among those 15 patients, 5 recovered their sensory functions while the remaining 10 showed improvements at the end of the 6-day treatment period.
• 31 out of 37 COVID-19 patients, representing approximately 83.8% of patients, reported the elimination of one or more symptoms after taking 1 full dose of RGC-COV19TM (1 day of treatment) with the largest number of symptoms eliminated after 1 day of treatment being 7.
• Out of the 37 patients, 9 patients experienced a combination of dyspnea (d
...
Read more »
|
SHENZHEN, China-Friday 18 February 2022 [ AETOS Wire ]
(BUSINESS WIRE) -- China’s leading vaping media, Bluehole New Consumption, today publishes an industry comment on BAT 2021 Preliminary Results
Here below is the full article in English:
By February 15, the 4 major tobacco companies, including British America Tobacco (BAT), Altria, Philip Morris International and Japan Tobacco International, have announced their 2021 full-year results. BAT reported a revenue of £25.68 billion ($34.82 billion), a 6.9% increase in 2021, being the top among the four major tobacco companies in revenue.
BAT's revenue rise is also largely driven by the strong sales growth of new tobacco products, including vapor, heated tobacco and oral products.
In 2021, BAT recorded an "accelerating New Category revenue growth" of 50.9%, with 59% revenue surge in vapor products. By the end of 2021, there are more than 18.3 million adult consumers using
...
Read more »
|
DARMSTADT, Germany -Friday 18 February 2022 [ AETOS Wire ]
38-month median follow-up data from the Phase III JAVELIN Bladder 100 trial demonstrated prolonged median OS of 23.8 months with BAVENCIO plus best supportive care (BSC) in the first-line maintenance setting versus a median OS of 15.0 months with BSC alone
BAVENCIO continues to be the first and only immunotherapy to improve survival in the first-line setting in locally advanced or metastatic UC in a Phase III study
Not intended for US-, Canada- and UK-based media
(BUSINESS WIRE)-- Merck, a leading science and technology company, today announced the results of an exploratory analysis from the Phase III JAVELIN Bladder 100 trial with 19 additional months of follow-up data from the initial primary analysis. This analysis reinforced the original results and showed that BAVENCIO® (avelumab) plus best supportive care (BSC) in the first-line maintenance setting prolonged median overall survival (OS)
...
Read more »
|
Djibouti city, Djibouti-Friday 18 February 2022 [ AETOS Wire ]
The Saudi Fund for Development (SFD) has inaugurated two new development projects in the water and housing sector and laid the foundation stone for a project in the transportation sector in Djibouti, with a total amount of US$ 137 million dollars.
During an official visit to the East African nation, Saudi Fund for Development CEO, Sultan bin Abdulrahman Al-Marshad, met with the President of the Republic of Djibouti, H.E. Ismail Omar Guelleh to discuss the projects financed by SFD for economic and social development worth US$ 305 million since 1982.
As part of the visit Mr. Sultan bin Abdulrahman Al-Marshad and the Prime Minister of Djibouti, Mr. Abdoulkader Kamil Mohamed, inaugurated a new project to supply clean drinking water to 45,000 people in the coastal Province of Obock. Funded with a grant of US$ 10 million provided by Saudi Arabia through the SFD, it will involve the construction of 105km
...
Read more »
|
OSAKA, Japan & CAMBRIDGE, Massachusetts-Friday 18 February 2022 [ AETOS Wire ]
- Data on Patients with Complex Crohn’s Perianal Fistulas Were Presented at the European Crohn’s and Colitis Organisation (ECCO) 2022 Congress1
- INSPIRE is the First Observational, Multicenter, Post-Approval, Open-Enrollment Study Designed to Evaluate the Real-World Effectiveness and Safety of Alofisel (darvadstrocel)1
- Approved in the European Union/European Economic Area, Israel, Switzerland, United Kingdom and Japan, Alofisel, an Expanded Human Allogeneic Adipose-Derived Mesenchymal Stem Cell Therapy, Offers a Potential Cell-Mediated Closure Option for Patients with Complex Crohn’s Perianal Fistulas Who Have Shown an Inadequate Response to at Least One Conventional or Biologic Therapy3,4,5,6,7,8
(BUSINESS WIRE) -- Takeda (TSE:4502/NYSE:TAK) today announced the first six-month interim analysis results from INSPIRE, in which clinical remission* was
...
Read more »
|
|